WHO Collaborating Centre for Travel Medicine, Travel Clinic and Department of Public Health, Epidemiology, Biostatistics and Prevention Institute, University of Zürich, 8001, Zurich, Switzerland.
Centre for Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
Malar J. 2018 Nov 29;17(1):443. doi: 10.1186/s12936-018-2586-9.
Recent reports highlight malaria as a frequent diagnosis in migrants who originate from Eritrea. A descriptive analysis of GeoSentinel cases of malaria in Eritrean migrants was done together with a literature review to elucidate key attributes of malaria in this group with a focus on possible areas of acquisition of malaria and treatment challenges.
A total of 146 cases were identified from the GeoSentinel database from 1999 through September 2017, with a marked increase in 2014 and 2015. All patients originated from Eritrea and the main reporting GeoSentinel sites were in Norway, Switzerland, Sweden, Israel and Germany. The majority of patients (young adult males) were diagnosed with malaria following arrival in the host country. All patients had a possible exposure in Eritrea, but may have been exposed in documented transit countries including Ethiopia, Sudan and possibly Libya in detention centres. Most infections were due to Plasmodium vivax (84.2%), followed by Plasmodium falciparum (8.2%). Two patients were pregnant, and both had P. vivax malaria. Some 31% of the migrants reported having had malaria while in transit. The median time to onset of malaria symptoms post arrival in the host country was 39 days. Some 66% of patients were hospitalized and nine patients had severe malaria (according to WHO criteria), including five due to P. vivax.
The 146 cases of mainly late onset, sometimes severe, P. vivax malaria in Eritrean migrants described in this multi-site, global analysis reflect the findings of single-centre analyses identified in the literature search. Host countries receiving asylum-seekers from Eritrea need to be prepared for large surges in vivax and, to a lesser extent, falciparum malaria, and need to be aware and prepared for glucose-6-phosphate dehydrogenase deficiency testing and primaquine treatment, which is difficult to procure and mainly unlicensed in Europe. There is an urgent need to explore the molecular epidemiology of P. vivax in Eritrean asylum-seekers, to investigate the area of acquisition of P. vivax along common transit routes and to determine whether there has been re-introduction of malaria in areas, such as Libya, where malaria is considered eliminated, but where capable vectors and Plasmodium co-circulate.
最近的报告强调,来自厄立特里亚的移民中疟疾是常见的诊断。对 GeoSentinel 中厄立特里亚移民疟疾病例进行了描述性分析,并结合文献回顾,阐明了该人群中疟疾的关键特征,重点关注疟疾可能的获得途径和治疗挑战。
从 1999 年到 2017 年 9 月,从 GeoSentinel 数据库中确定了 146 例病例,2014 年和 2015 年明显增加。所有患者均来自厄立特里亚,主要报告的 GeoSentinel 地点在挪威、瑞士、瑞典、以色列和德国。大多数患者(年轻成年男性)在抵达东道国后被诊断患有疟疾。所有患者均在厄立特里亚有感染可能,但可能在埃塞俄比亚、苏丹和可能的利比亚拘留中心等有记录的过境国感染。大多数感染是由间日疟原虫(84.2%)引起的,其次是恶性疟原虫(8.2%)。两名患者为孕妇,均患有间日疟。约 31%的移民报告在过境时患有疟疾。抵达东道国后疟疾症状发作的中位数时间为 39 天。约 66%的患者住院,9 例患者患有重症疟疾(根据世界卫生组织标准),其中 5 例为间日疟。
在这项多地点、全球性分析中,描述了 146 例厄立特里亚移民中主要为迟发性、有时为重症的间日疟,这反映了文献检索中确定的单中心分析结果。接收厄立特里亚寻求庇护者的东道国需要为大量间日疟和(在较小程度上)恶性疟的涌入做好准备,需要意识到并准备好进行葡萄糖-6-磷酸脱氢酶缺乏症检测和伯氨喹治疗,这在欧洲难以获得,且主要未获许可。迫切需要探索厄立特里亚寻求庇护者中间日疟原虫的分子流行病学,调查常见过境路线上间日疟原虫的获得区域,并确定疟疾是否在利比亚等被认为已消除疟疾的地区重新出现,而这些地区有能力的病媒和疟原虫共同传播。